news

Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%

Jul 28, 2026 · Source: cision
Chandigarh University Researchers Develop an Economical Device for Accurate Drug Absorption Studies; to Help in Reducing Cost of Medicines by 40%

Chandigarh University researchers get patent for an energy-efficient, economical device for accurate drug absorption studies

CHANDIGARH, India, July 28, 2026 -- A team of researchers at Chandigarh University has developed an innovative laboratory device that could significantly improve the way oral medicines are tested during development, enabling more accurate, reliable and cost-effective drug absorption studies that can ultimately support the development of safer and more effective medicines. By addressing several long-standing limitations in conventional drug absorption equipment, the innovation enables researchers to generate more dependable experimental data while reducing the likelihood of failed studies, repeated experiments and unnecessary research costs. The improved version of the apparatus also reduces the size and complexity of the conventional equipment, resulting in a 40 per cent reduction in operational costs and making a low-cost version of the device available for pharmaceutical research and routine laboratory use.

Research Scholar, Prof. Dr. Satbir Singh Sehgal while holding the patent certificate ‘Improved Oral Drug Absorption Study Cell’ granted by the Indian Patent Office

Recognizing the novelty and practical significance of the innovation, the Indian Patent Office has granted the Chandigarh University researchers a patent for their invention titled 'Improved Oral Drug Absorption Study Cell'. The innovation, developed by Chandigarh University researchers, Prof. (Dr.) S.S. Sehgal and Prof. (Dr.) Manish Goswami (former professor at University Institute of Pharmaceutical Sciences), Chandigarh University, has been granted a patent by the Indian Patent Office for its novel design. The patented device introduces engineering improvements that overcome several limitations of the conventional drug absorption apparatus while remaining simple to manufacture, economical to operate and suitable for routine laboratory use.

The reliable drug absorption studies form the foundation of oral medicine development, helping scientists determine whether a medicine administered orally can efficiently cross the intestinal barrier and enter the bloodstream before it progresses to advanced stages of research. More accurate laboratory data allows researchers to optimise formulations much earlier in the development cycle, reducing uncertainty before medicines move to expensive pre-clinical and clinical evaluation while strengthening confidence in pharmaceutical research.

Sharing details and significance of the innovation, Prof. (Dr.) S.S. Sehgal said, "Drug absorption studies are among the most important stages in oral drug development because they help scientists understand how efficiently a medicine is likely to be absorbed before it progresses to advanced stages of research. The conventional drug absorption equipment offer very limited space, forcing researchers to fold the everted intestinal tissue inside the chamber. This places unnecessary stress on the tissue, affects its natural positioning and can result in variability into the drug experimental observations. In many cases, tissue damage or improper placement can even result in experimental failure that forces researchers to repeat the study and increase both development time and research costs."

Prof. Sehgal added, "Instead of altering the testing methodology, we redesigned the apparatus to address the limitations of conventional systems. By introducing an extended side arm, our equipment allows the tissue to remain in a natural U-shaped position helping in proper drug absorption to occur under consistent conditions. Along with improved temperature uniformity, better mixing of the drug solution and greater operational stability, the redesigned apparatus helps generate more accurate and reproducible data that can improve the evaluation of oral drug formulations."

Highlighting the broader impact of the invention, Prof. (Dr.) Manish Goswami said, "Scientific progress is often driven by improving the tools researchers use every day. Even relatively small improvements in laboratory equipment can have a significant impact on the quality of research data. By making drug absorption studies more reliable and easier to perform, this innovation can support pharmaceutical scientists in developing better oral formulations and ultimately contribute to medicines that offer greater therapeutic effectiveness for patients."

Elaborating on the improvements, Dr. Manish Goswami said, "Our objective was to improve the reliability of the experiment through a simple yet effective engineering solution. One of the biggest advantages of this innovation is that it minimizes variations during sample collection, making drug absorption studies more reliable and consistent. The device features a compact design built using laboratory-grade materials such as borosilicate and Teflon-coated glass to ensure durability and precision. At the same time, its optimized architecture reduces the overall size of the apparatus, simplifies fabrication and handling, and lowers operational costs by 40 per cent, making it an economical solution for pharmaceutical research. These improvements create more consistent and reproducible experimental conditions, enabling researchers to generate higher-quality data without adding complexity to the procedure."

The innovation is expected to benefit through its application in pharmaceutical industry, drug discovery and development sector, pharmaceutical R&D centres, Contract Research Organizations (CROs), Clinical Research Organizations (CROs), universities and pharmacy colleges, government research laboratories and regulatory testing laboratories where drug absorption studies are routinely carried out for formulation development, pre-clinical research and evaluation of oral medicines.

Apart from improving the experimental accuracy, the redesigned apparatus also reduces operational complexity by eliminating the need for extra heating arrangements. Its simplified design lowers energy requirements, improves laboratory efficiency and reduces overall operating costs, making it suitable for routine use across pharmaceutical laboratories, academic institutions and research organisations.

With oral medicines accounting for the majority of pharmaceutical formulations used worldwide, improvements in early-stage drug absorption studies can strengthen the entire drug development process. By enabling more reliable laboratory testing while reducing time, cost and experimental variability, Chandigarh University's patented innovation has the potential to support faster formulation optimisation, improve pharmaceutical research and contribute to the development of safer, more effective oral medicines for patients across the globe.

About Chandigarh University

Chandigarh University is a NAAC A+ Grade University and QS World Ranked University. This autonomous educational institution is approved by UGC and is located near Chandigarh in the state of Punjab. It is the youngest university in India and the only private university in Punjab to be honoured with A+ Grade by NAAC (National Assessment and Accreditation Council). CU offers more than 109 UG and PG programs in the field of engineering, management, pharmacy, law, architecture, journalism, animation, hotel management, commerce, and others. It has been awarded as The University with Best Placements by WCRC.

Website address: https://www.cuchd.in/

Cision View original content to download multimedia:https://www.prnewswire.com/in/news-releases/chandigarh-university-researchers-develop-an-economical-device-for-accurate-drug-absorption-studies-to-help-in-reducing-cost-of-medicines-by-40-302836315.html

Comments (0)

Login to join the conversation

Login / Register

No comments yet. Be the first to comment!

More to Read

Aarti Industries Delivers Promising Q1 FY27; Reaffirms Long-Term Growth Outlook
news
Jul 30, 2026 1 min

Aarti Industries Delivers Promising Q1 FY27; Reaffirms Long-Term Growth Outlook

MUMBAI, India , July 30, 2026 -- Aarti Industries Limited (AIL), a leading global speciality chemicals company, today announced its consolidated financial results for the first quarter ended June 30, 2026. The results were approved by the Board of Directors at its meeting held earlier today. The Company delivered a strong start to FY27, reporting approximately 79% year-on-year and 13% quarter-on-quarter EBITDA growth, driven by an optimised product mix, inventory, and forex gains despite volume degrowth in a challenging global operating environment.

SEMI Announces New Spring Schedule for SEMICON West Beginning March 30-April 1, 2027
news
Jul 30, 2026 1 min

SEMI Announces New Spring Schedule for SEMICON West Beginning March 30-April 1, 2027

Phoenix to Become the Long-term Home of North America s Premier Semiconductor Industry Event MILPITAS, Calif. , July 30, 2026 -- SEMI , the global industry association serving the semiconductor and electronics design and manufacturing supply chain, today announced a significant evolution for SEMICON West , establishing a new annual spring schedule beginning March 30 April 1, 2027, at the Phoenix Convention Center in Phoenix, Arizona.

Elevated Materials Strengthens Commercial Leadership with Appointment of Jay Wang as Chief Revenue Officer
news
Jul 30, 2026 1 min

Elevated Materials Strengthens Commercial Leadership with Appointment of Jay Wang as Chief Revenue Officer

Jay Wang brings global commercial leadership across semiconductors, LEDs, and advanced battery markets as Elevated Materials expands customer adoption of its ultra-thin lithium films. SANTA CLARA, Calif. , July 30, 2026 -- Elevated Materials, a leading manufacturer of ultra-thin lithium films for next-generation batteries, today announced the appointment of Jay Wang as Chief Revenue Officer. Jay brings more than two decades of global sales, business development, and general management experience across battery, semiconductors, LEDs, and advanced technology markets. He has led commercial organizations across Asia and the United States, building high-performing teams, expanding customer relationships, and driving revenue growth across automotive, consumer electronics, AI, networking, IoT, and industrial markets.

Frost & Sullivan Marks 65 Years of Identifying ICT Growth Opportunities
news
Jul 30, 2026 1 min

Frost & Sullivan Marks 65 Years of Identifying ICT Growth Opportunities

Deep sector expertise and AI-powered intelligence help organizations turn technological disruption into growth LONDON , July 30, 2026 -- As Frost & Sullivan celebrates its 65th anniversary, the company is reflecting on its long-standing role in helping organisations anticipate technological change, navigate disruption and identify transformational growth opportunities across the information and communications technology (ICT) landscape.

NYSE Content Update: Jersey Mike's Raises $1 Billion Ahead of NYSE Debut
news
Jul 30, 2026 1 min

NYSE Content Update: Jersey Mike's Raises $1 Billion Ahead of NYSE Debut

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , July 30, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today s NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on July 30th Jersey Mike s Subs (NYSE: JMKE) and Reformation (NYSE: REF) will begin trading on the NYSE today following their respective IPOs. Jersey Mike s offers more than 43 million shares at 23 a piece. Jersey Mike s CEO Charlie Morrison will join NYSE Live to discuss the firm s next move after going public. Reformation raises 211 million in its Initial Public Offering. Investors are dissecting Wednesday s policy decision from the Federal Reserve and parsing through fresh earnings data.

DXC Announces Leadership Appointments to Accelerate Its AI-Centric Future
news
Jul 30, 2026 1 min

DXC Announces Leadership Appointments to Accelerate Its AI-Centric Future

Paul Taylor named President of DXC; Dan Gray to lead Global Infrastructure Services ASHBURN, Va. , July 30, 2026 -- DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced a series of leadership appointments effective immediately that position the next generation of AI-centric leadership at the forefront of the company and further streamline the organization for customers, partners, and employees. Paul Taylor has been named President of DXC Technology, assuming the role from Raul Fernandez, who continues as Chief Executive Officer. In addition, Dan Gray has been appointed President of Global Infrastructure Services (GIS). Ramnath Venkataraman, President of Consulting & Engineering Services (CES), and Ray August, President of Insurance Software & Business Process Services (ISB), will continue to lead their businesses, with all three offering presidents reporting to Taylor. Chris Drumgoole, currently President of GIS, will depart DXC to take on an elevated leadership role outside the company and will join as a founding member of DXC s newly formed CEO Advisory Council.

How Dubai Successfully Turned the Summer Break into a Platform for Prevention and Positive Youth Development
news
Jul 30, 2026 1 min

How Dubai Successfully Turned the Summer Break into a Platform for Prevention and Positive Youth Development

DUBAI, UAE , July 30, 2026 -- Rather than viewing the summer break as time away from learning, Dubai has turned it into an opportunity to strengthen prevention, discipline, safety awareness and positive values among young people through Dubai Police s Hemaya International Centre. This year, the centre s Summer Student Programme graduated 1,402 students from 31 nationalities, bringing the total number of graduates since 2018 to 10,792 students representing 175 nationalities.

WEKA and Andromeda Partner to Power AI Workloads at Global Scale
news
Jul 30, 2026 1 min

WEKA and Andromeda Partner to Power AI Workloads at Global Scale

Partnership delivers consistent, high-performance AI storage across Andromeda s global provider network, lowering the total cost of innovation for AI teams CAMPBELL, Calif. , July 30, 2026 -- WEKA , the AI data and memory infrastructure company, today announced that Andromeda , the platform connecting AI teams with high-performance compute, is integrating the WEKA NeuralMesh platform as a core AI data storage layer for managed GPU clusters. Andromeda s customers can now access a dedicated NeuralMesh or a GPU-native WEKA NeuralMesh Axon deployment to achieve consistent storage performance across any cluster running on any hyperscaler or AI cloud.